The author J.K. Rowling has donated £15.3m to the University of Edinburgh to help improve the lives of people with multiple sclerosis (MS) and similar conditions. The investment – which is inclusive of Gift Aid – will help create new facilities and support vital research at the University’s Anne Rowling Regenerative Neurology Clinic. Anne Rowling The Clinic was set up following a previous donation from...
TC BioPharm (TCB), a developer of allogeneic CAR-T immuno-oncology products, and leaders in Gamma Delta T (GDT) cell therapies, today announced it has initiated a Phase I clinical study of TCB002, an allogeneic cell therapy consisting of activated and expanded gamma delta T cells. The trial, for treatment of patients suffering from Acute Myeloid Leukemia (AML), is being conducted at the Institute of Hematology and...
TC BioPharm (TCB), leaders in the development of tumor-targeting gamma delta T (GDT) cells, today announced that Professor John Anderson has been appointed as Scientific and Medical Director. He joins as the company executes clinical translation of the first candidates from a development pipeline of genetically modified “off the shelf” CAR-T products. As a distinguished clinical investigator and academic researcher, John’s breadth of expertise and...
RoslinCT, a leading cell gene therapy contract manufacturing organisation, is pleased to announce the appointment of David Bowie to the Board of Directors. David has over twenty-eight years of international sales, marketing management and business development experience in the global healthcare sector which led him to the board of the Scottish Government backed Life Science Scotland industry Leadership Group for some 12 years. David brings...
Maxim Park has announced that tenant TC BioPharm (TCB) has extended its space at the Park by an additional 10,000 sq ft, on a ten-year lease, within the Maxim 1 building. The immunotherapy company has been a tenant at the Park since 2014, when it took 5,000 sq ft on an initial ten-year lease to build facilities for the development of novel treatments for various...
TC BioPharm (TCB) today announced it is collaborating with Dublin’s Trinity College to accelerate in-house production of V delta 1 γδ T cell banks for treatment of solid tumors. The collaboration with Dublin’s School of Medicine, Trinity College, will leverage extensive experience gained by Dr Derek Doherty related to the biology and culture expansion of V delta 1 γδ T cells. Dr Doherty and his...